Cipla gets EIR from USFDA for Invagen manufacturing facility

28 Jan 2020 Evaluate

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating closure of the inspection at the Invagen (US) manufacturing facility. The agency had conducted inspection from December 2, 2019 to December 6, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1490.00 10.40 (0.70%)
29-May-2024 14:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1489.95
Dr. Reddys Lab 5992.15
Cipla 1490.00
Zydus Lifesciences 1044.50
Lupin 1603.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.